Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xiaozao Technology is a China-based industrial biotechnology company focused on microalgae cultivation, extraction, and commercialization of omega-3 ingredients, especially EPA-rich algal oil. The company has built an integrated value chain spanning strain development, cultivation, downstream extraction, and finished product sales. Its products are positioned primarily in nutrition, nutraceutical, and health ingredient markets rather than traditional prescription therapeutics. Publicly described offerings include EPA algal oil, DHA algal oil, combined EPA+DHA oils, softgels, and algal powder products under the AlgaLab brand. The company appears to operate commercial production facilities in Guangxi and maintains corporate roots in Shenzhen, with later operations associated with Anji, Zhejiang. Overall, Xiaozao Technology looks like a commercial-stage health and biotech ingredients company centered on microalgae-derived omega-3 products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xiaozao Technology.